Verso Investment Management
Tracked across 1 events · 21 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Novartis shareholder whose analyst commented on the failure, reflecting investor concerns.
Sep 08, 2026 · 21 articles
ERGEN INTELLIGENCE
Track Verso Investment Management live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard